Dextromethorphan O-demethylation polymorphism in an African-American population

被引：15

作者：

He, N ^{[1
]}

Daniel, HI ^{[1
]}

Hajiloo, L ^{[1
]}

Shockley, D ^{[1
]}

机构：

[1] Meharry Med Coll, Dept Pharmacol, Clin Pharmacol Program, Nashville, TN 37208 USA

来源：

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 1999年 / 55卷 / 06期

关键词：

CYP2D6; genetic polymorphism; African-Americans;

D O I：

10.1007/s002280050656

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Objective: One hundred eighty-one (97 F, 84 M) unrelated healthy African-American subjects (aged 18-41 years) were phenotyped based on their dextromethorphan (DMP) O-demethylation ability. Methods: Each subject was given 15 mg DMP orally and collected 8-h urine. The concentrations of DMP and its metabolite dextrophan (DOP) were determined by HPLC with ultraviolet detection. Metabolic ratio (MR) was expressed as the ratio of DMP to DOP molar amount in urine. Results: The frequency distribution histogram of the MR was bimodal, and probit analysis of this frequency gave an antimode value of 0.34. Seven subjects [3.9%, 95% confidence interval (CI) 1.1%-6.7%] were classified as poor metabolizers (PMs). Conclusion: This deficient frequency is in complete agreement with the reported ones in two smaller investigations in the African-American populations.

引用

页码：457 / 459

页数：3

共 12 条

[1] CHROMOSOMAL ASSIGNMENT OF HUMAN CYTOCHROME-P-450 (DEBRISOQUINE SPARTEINE TYPE) TO CHROMOSOME 22 [J].

EICHELBAUM, M ;

BAUR, MP ;

DENGLER, HJ ;

OSIKOWSKAEVERS, BO ;

TIEVES, G ;

ZEKORN, C ;

RITTNER, C .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 23 (04) :455-458

[2] OXIDATION PHENOTYPE - A MAJOR DETERMINANT OF METOPROLOL METABOLISM AND RESPONSE [J].

LENNARD, MS ;

SILAS, JH ;

FREESTONE, S ;

RAMSAY, LE ;

TUCKER, GT ;

WOODS, HF .

NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (25) :1558-1560

[3] DEBRISOQUIN AND MEPHENYTOIN HYDROXYLATION PHENOTYPES AND CYP2D6 GENOTYPE IN PATIENTS TREATED WITH NEUROLEPTIC AND ANTIDEPRESSANT AGENTS [J].

LLERENA, A ;

HERRAIZ, AG ;

COBALEDA, J ;

JOHANSSON, I ;

DAHL, ML .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (06) :606-611

[4]

LYUN AO, 1986, CLIN PHARMACOL THER, V40, P387

[5] DEXTROMETHORPHAN POLYMORPHIC HEPATIC OXIDATION (CYP2D6) IN HEALTHY BLACK-AMERICAN ADULT SUBJECTS [J].

MARINAC, JS ;

FOXWORTH, JW ;

WILLSIE, SK .

THERAPEUTIC DRUG MONITORING, 1995, 17 (02) :120-124

[6] A STUDY OF THE DEBRISOQUINE HYDROXYLATION POLYMORPHISM IN A NIGERIAN POPULATION [J].

MBANEFO, C ;

BABABUNMI, EA ;

MAHGOUB, A ;

SLOAN, TP ;

IDLE, JR ;

SMITH, RL .

XENOBIOTICA, 1980, 10 (11) :811-818

[7] QUANTITATIVE-DETERMINATION OF DEXTROMETHORPHAN AND 3 METABOLITES IN URINE BY REVERSE-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].

PARK, YH ;

KULLBERG, MP ;

HINSVARK, ON .

JOURNAL OF PHARMACEUTICAL SCIENCES, 1984, 73 (01) :24-29

[8] LOWER PREVALENCE OF THE DEBRISOQUIN OXIDATIVE POOR METABOLIZER PHENOTYPE IN AMERICAN BLACK VERSUS WHITE SUBJECTS [J].

RELLING, MV ;

CHERRIE, J ;

SCHELL, MJ ;

PETROS, WP ;

MEYER, WH ;

EVANS, WE .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (03) :308-313

[9] DEBRISOQUINE AND METOPROLOL OXIDATION IN ZAMBIANS - A POPULATION STUDY [J].

SIMOOYA, OO ;

NJUNJU, E ;

HODJEGAN, AR ;

LENNARD, MS ;

TUCKER, GT .

PHARMACOGENETICS, 1993, 3 (04) :205-208

[10] POLYMORPHISM OF THE 4-HYDROXYLATION OF DEBRISOQUINE IN THE SAN-BUSHMEN OF SOUTHERN-AFRICA [J].

SOMMERS, D ;

MONCRIEFF, J ;

AVENANT, J .

HUMAN TOXICOLOGY, 1988, 7 (03) :273-276

← 1 2 →